Putting the brakes on “budding” viruses
New measles, Nipah research offers a window into viral assembly
LA JOLLA, CA — Paramyxoviruses have the potential to trigger a devastating pandemic. This family of viruses includes measles, Nipah virus, mumps, Newcastle disease and canine distemper.
“The infectiousness of measles is unmatched by any known virus. If one person with measles coughs in a room with 100 unvaccinated people, around 90 would become infected,” says Michael Norris, Ph.D., a former postdoctoral associate at La Jolla Institute for Immunology (LJI) and current assistant professor at the University of Toronto. “Nipah virus is not as contagious, but it is incredibly lethal, with between 40 percent and 90 percent of infections causing death.”
“Just imagine if a paramyxovirus emerged that was as contagious as measles and as deadly as Nipah,” Norris adds.
It’s not hard to picture that scenario. In fact, the 2011 film Contagion was based on this exact kind of imagined paramyxovirus.
Now Norris and an international team of collaborators have published the first-ever look at a key stage in the life cycles of measles and Nipah viruses. Their new study, published as an upcoming cover story in Science Advances, reveals how future therapies might stop these viruses in their tracks.
“This work solves a long-standing mystery: how viruses assemble themselves,” says LJI Professor Erica Ollmann Saphire, Ph.D., who served as study co-senior author with Professor Robert Stahelin, Ph.D., of Purdue University. “We know that a virus’s many pieces come together at the cell membrane, but we didn’t know what the trigger was that starts that irreversible assembly process.”
“This study succeeds by identifying how paramyxoviruses are able to utilize a host cell lipid for viral spread,” says Stahelin. “This work will inform future drug discovery endeavors.”
Assembling a paramyxovirus
The researchers used several imaging techniques, including x-ray crystallography and electron microscopy, to capture a process called viral assembly.
During viral assembly, key proteins and genetic material rush to specific areas on infected host cell membranes. Special virus proteins, called “matrix” proteins, come together to form a lattice against the inside of the cell membrane. Matrix proteins are the drivers of the virus assembly process. Norris calls them the “field marshals” that gather and guide the other proteins needed to form a new virus. Matrix proteins also give a virus its shape.
This image shows how viral proteins gather inside a cell membrane to form a sort of bubble before “budding” off to spread infection. Image by Michael Norris, Ph.D.
As viral assembly continues, the lattice of matrix proteins begins to push the membrane outward to form a “bud” and recruits other viral proteins to this site. Once the bud has all the needed components in place, it splits away from the parent cell to form a new virus that can then infect a new host cell.
Researchers hope by understanding viral assembly better, they can design therapies that interrupt the process. This approach holds promise; the drug Lenacapavir targets the assembly process of HIV and is in clinical trials right now, and Norris says there’s potential to use the same strategy to stop paramyxoviruses. “This HIV therapy is a proof of principle that targeting viral assembly is a viable strategy for drug development,” says Norris.
Scientists just need a clear view of the paramyxovirus assembly process. The challenge for researchers is trying to see the matrix proteins in action.
Capturing viral assembly
Norris and his colleagues examined viral assembly in both measles virus and Nipah virus. Their analysis shows how two matrix proteins come together in a sort of hug to form a two-sided “dimer” structure. The researchers demonstrated that stopping this “hug” by blocking formation of this dimer also stops viral assembly—but that wasn’t surprising.
The researchers really needed to know how these dimers interact with other structures during the budding process. They showed that the dimer hug floats toward the inside of the cell membrane to sort of bump heads with the membrane.
From work spearheaded by the Stahelin Lab at Purdue University, the team found that the matrix proteins specifically bind to a lipid molecule in the host cell membrane called PI(4,5)P2. This interaction anchors matrix proteins to the host cell membrane surface and provides meeting points for virus assembly at specific sites along the membrane. Norris and his colleagues captured this interaction in detail using x-ray crystallography.
Then came a big structural surprise. The team found that Nipah virus matrix proteins actually change their structure to open up a lipid-binding pocket for PI(4,5)P2.
“This was an extremely exciting aspect of the study,” says Norris. He emphasizes that this pocket doesn’t exist prior to membrane binding—and the pocket would not have been spotted without the structure captured in this study. The discovery of this pocket revealed a brand-new target for developing inhibitors of the assembly process.
PI(4,5)P2 also turned out to be the secret ingredient that triggers matrix protein dimers to bind to one another to form a lattice on the inner surface of the host cell membrane. When the matrix proteins change their structure to open the PI(4,5)P2 pocket, they also adopt a shape that drives lattice assembly.
This change in the matrix protein structure also puts a bend in the cell membrane. Before PI(4,5)P2 binding, the space between two matrix proteins in a hug has a concave bowl shape with angled sides. After PI(4,5)P2 binding to the matrix proteins, these angled sides flatten to transform the bowl shape to a plate shape and force the membrane to curve upward. The soft curve of the cell membrane then pops up to start forming a new bud that will eventually make up a new virus.
The scientists learned a lot from these structures. “We didn’t know how much the molecules would change as the process was triggered or what the structure would look like as they zip together,” says Saphire.
Designing a broad therapeutic
Measles is still a major killer around the world. India and Bangladesh deal with yearly Nipah outbreaks. These viruses aren’t going away, and we need effective therapies to stop outbreaks.
A broad paramyxovirus therapy could also protect livestock from disease and ensure food security. Newcastle disease in poultry is caused by paramyxovirus infections that can wipe out entire flocks before symptoms are even detected. An outbreak of Newcastle disease in 2018-2020 in California caused the culling of 1.2 million birds.
The new study shows the potential for a pan-paramyxovirus therapy that targets viral assembly in multiple viruses. Norris points out that while the genomes of measles and Nipah viruses are very different, the measles and Nipah matrix proteins look almost identical.
“Because these matrix protein structures are highly conserved, we could potentially target one virus and have an inhibitor that could target all the rest of the viruses in this family,” says Norris.
Norris was able to start looking for matrix protein inhibitors thanks to funding from LJI’s Tullie and Rickey Families SPARK Award for Innovation in Immunology. This funding allowed him to rapidly narrow down a list of over 7.4 million drug candidates to identify around 100 that will go into further testing.
The next steps are to better understand the molecular interactions that make up the matrix lattice and to better understand how matrix proteins recruit and interact with the other viral proteins during the assembly process.
“We’re looking at leveraging this work to design broad-spectrum inhibitors of viral assembly,” says Norris.
Additional authors of the study, “Measles and Nipah virus assembly: specific lipid binding drives matrix polymerization,” include Monica L. Husby, William B. Kiosses, Jieyun Yin, Roopashi Saxena, Linda J. Rennick, Anja Heiner, Stephanie S. Harkins, Rudramani Pokhrel, Sharon L. Schendel, Kathryn M. Hastie, Sara Landeras-Bueno, Zhe Li Salie, Benhur Lee, Prem P. Chapagain , Andrea Maisner, and W. Paul Duprex.
This study was supported by the National Institutes of Health (grants NIH/NIAID AI081077, NIH S10OD027043, AI125536, and AI123449), Henry L. Hillman Foundation, the Deutsche Forschungsgemeinschaft (German Research Foundation, 197785619-1012 SFB 1021), and institutional funds of the La Jolla Institute for Immunology.
###
About La Jolla Institute
The La Jolla Institute for Immunology is dedicated to understanding the intricacies and power of the immune system so that we may apply that knowledge to promote human health and prevent a wide range of diseases. Since its founding in 1988 as an independent, nonprofit research organization, the Institute has made numerous advances leading toward its goal: life without disease. Visit lji.org for more information.
